Enliven Therapeutics
ELVN
ELVN
61 hedge funds and large institutions have $534M invested in Enliven Therapeutics in 2023 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 22 increasing their positions, 22 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less ownership
Funds ownership: →
less funds holding
Funds holding: →
less funds holding in top 10
Funds holding in top 10: →
25% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 8
33% less capital invested
Capital invested by funds: $798M → $534M (-$264M)
Holders
61
Holding in Top 10
5
Calls
$151K
Puts
–
Top Buyers
| 1 | +$9.9M | |
| 2 | +$7.56M | |
| 3 | +$5.41M | |
| 4 |
FLSM
Frazier Life Sciences Management
Palo Alto,
California
|
+$3M |
| 5 |
Charles Schwab
San Francisco,
California
|
+$1.29M |
Top Sellers
| 1 | -$9.83M | |
| 2 | -$8.71M | |
| 3 | -$4.44M | |
| 4 |
Bank of Montreal
Toronto,
Ontario, Canada
|
-$3.95M |
| 5 |
Janus Henderson Group
London,
United Kingdom
|
-$1.29M |